Abstract
The adult human body contains 1.3 kg of calcium of which 99% is contained in bones and teeth, 1% in cells of soft tissue, and 0.15% in the extracellular fluid (1). The bone calcium is in the form of hydroxyapatite crystals, and the exchange of calcium between bone and extracellular fluid occurs by two mechanisms: bone turnover, which is concerned with replacement and remodeling of bone and involves coupled osteoclastic resorption and osteblastic deposition, and homeostatic equilibration, which is concerned with the regulation of the plasma calcium level (2, 3). The normal total plasma calcium concentration is 4.5–5.1 mEq/1 (9–10.2mg/dl). Of the total calcium 40–43% is bound to plasma protens (mainly albumin), 5–10% is combined with anions such as citrate and phosphate to form nonionized complexes, and the remaining 40–50% is free ionized calcium. Only this last fraction is physiologically active. In addition, a small amount of calcium is also bound to serum globulins.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Parfitt AM, Kleerekoper M: The divalent ion homeostasis system. Physiology and metabolism of calcium, phosphorus, magnesium and bone. In: MH Maxwell, CR Kleeman, eds, Clinical Disorders of Fluid & Electrolyte Metabolism. McGraw-Hill, New York, p269, 1980.
Parfitt AM: The actions of parathyroid hormone on bone. 1. Metabolism 25:809, 1976.
Parfitt AM: The actions of parathyroid hormone on bone. II. Metabolism 25:904, 1976.
Loken HF, Havell RJ, Gordon GS, Wittinton SL: Ultra-centrifugal analysis of protein-bound and free calcium in human serum. J Biol Chem 235:3654, 1960.
Moore EW: Ionized calcium in normal serum, ultrafiltrates and whole blood determined by ion exchange electrodes. J Clin Invest 49:318, 1970.
Pedersen KO: The effect of bicarbonate pCO2 and pH on serum calcium fractions. Scand J Clin Lab Invest 27:145, 1970.
Walser M, Robinson BH, Duckett JW: The hypercalcemia of adrenal insufficiency. J Clin Invest 42:456, 1963.
Jaffe JP, Mosher DF: Calcium binding by a myeloma protein. Am J Med 67:343, 1979.
Lim P, Jacob E, Chio LF, Pwee HS: Serum ionized calcium in nephrotic syndrome. Q J Med 179–421, 1973.
Berry EM, Gupta MM, Turner SJ, Burns RR: Variations in plasma calcium with changes in plasma specfic gravity, total protein and alburmin. Br Med J 4:640, 1973.
Husdan H, Rapoport A, Lock S: Influence of posture on the serum concentration of calcium. Metabolism 22:787, 1973.
Raisz LG: Physiologic and pharmacologic regulation of bone resoprtion. N Engl J Med 282:909, 1973.
Slatopolsky E, Martin K, Morrissey J, Hruska K: Parathyroid hormone secretion metabolism and biologic actions. Semin Nephrol 1:319, 1981.
Kleeman CR, Bernstein D, Rockney R, Dowling JT, Maxwell M H: Studies on the renal clearance of diffusible calcium and the role of parathyroid glands on its regulation. Yale J Biol Med 34:1, 1961.
Widrow SH, Levinsky NG: The effect of parathyroid extract on renal tubular calcium reabsorption in the dog. J Clin Invest 41:2151, 1982.
Massry SG, Coburn JW, Chapman LW, Kleeman CR: Role of serum calcium, parathyroid hormone and NaCl infusion, on renal calcium and Na clearances. Am J Physiol 214:1403, 1968.
Shareghi GR, Stoner LC: Calcium transport across segments of the rabbit distal nephron in vitro. Am J Physiol 235:F367, 1978.
Greger R, Lang F, Oberleithner H: Distal site of calcium reabsorption into the rat nephron. Pflügers Arch 374:153, 1978.
Favus MJ. Transport of calcium by intestinal mucosa. Semin Nephrol 1:306, 1981.
Myrtle JF, Norman AW: Vitamin D: A cholecalciferol metabolite highly active in promoting intestinal calcium transport. Science 171:79, 1971.
Walling MW: Intestinal calcium and phosphate transport. Differential responses to Vitamin D3 metabolites. Am J Physiol 233:E488, 1977.
Lee DBN, Brautbar N, Massry SG Renal production and biologic actions of vitamin D metabolites. Semin Nephrol 1:335, 1981.
Hirsch PE, Munson PL: Thyrocalcitonin. Physiol Rev 49:548, 1969.
Copp DH: Endocrine regulation of calcium metabolism. Ann Review Physiol 32:61, 1970.
Nicolayson R: The absorption of calcium as a function of body saturation with calcium. Acta Physiol Scand 6:201, 1943.
Boyle IT, Gray RW, DeLuca HF: Regulation by calcium of in vivo synthesis of 1,25 hydroxycholecalciferol and 21,25 hydroxycholecalciferol. Proc Natl Acad Sci USA 68:2131, 1971.
DeCristofaro JB, Tsang, RC: Calcium (review). Emerg Med Clin North Am 4(2):207.21, 1986.
Parfitt AM: Equilibrium and disequilibrium hypercalcemia. New light on and old concept. Metab Bone Dis Related 1:279, 1979.
Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE: Biochemical evaluation of patients with cancer associated with hypercalcemia. Evidence for humoral and non-humoral groups. N Engl J Med 303:1377, 1980.
Mundy RG: Pathogenesis of hypercalcemia of malignancy (review). Clin Endocrinol (Oxford) 23:705, 1985.
Mundy RG, Raisz LG, Cooper RA, Schechter GP, Salmon SE: Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 291:1041, 1974.
Ralston SH, Fogelman I, Gardiner MD, Boyle IT: Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcemia in malignancy. Br Med J 288:1405, 1984.
Breslau NA, McGuire JL, Zerwekh JE, Frenkl EP, Pak CYC: Hypercalcemia associated with increased serum calcitriol levels in 3 patients with lymphoma. Ann Int Med 100:1, 1984.
Mosley JM, Kubota M, Diefenbach-Jagger H, Wettenhall REH, Kemp BE, Suva LJ, Rodda CP, Ebeling PR, Hudson PJ, Zajac JD, Martin TJ: Parathyroid hormone-related protein purified from a human lung cancer cell line. Bone Mineral Research Congress (ASBMR), Abs No. 391, Indianapolis, 1987.
Stewart AF, Wu T, Goumas D, Burtis WJ: Amino-terminal sequence of a human HHM-associated adenylate cyclase-stimulating protein contains PTH-like and PTH-unlike domains. Bone Mineral Research Congress (ASBMR), Abs No. 392, Indianapolis, 1987.
Katz A, Kaplan L, Massry SG, Heller R, Plotkin D, Knight I: Primary hyperparathyroidism in patients with breast carcinoma. Arch Surg 101:582, 1970.
Kaplan L, Katz AD, Ben Isaac C, Massry SG: Malignant neoplasms and parathyroid adenomas. Cancer 28:401, 1971.
Far HW, Fahey TJ Jr, Nash AG, Farr CM: Primary hyperparathyroidism in cancer. Am J Surg 126:539, 1973.
Samaan NA, Hickey RC, Hill CS Jr, Medellin H, Gates R B: Parathyroid tumors. Preoperative localization and association with other tumors. Cancer 33:933, 1974.
Vichayanrat A, Abramides A, Gardner B, Wallach S, Carter A C: Primary hyperparathyroidism in breast cancer. Am J Med. 61:136, 1976.
Singer FR, Sharp CF, Rude R K: Pathogenesis of hypercalcemic malignancy. Miner electrolyte Metab 2:161, 1979.
Robinson RG, Kerwin DM, Tsou E: Parathyroid adenoma with coexistent sarcoid granulomas. Hypercalcemic patient. Arch Intern Med 140: 1980.
Case records of the Massachusetts General Hospital: Weekly clinicopathological exercises. Case 50–1981. N Engl J Med 305:1457, 1981.
Farr HW, Fahey TJ Jr, Nash AG, Farr CM: Primary hyperparathyroidism and cancer. Am J Surg 126:539, 1973.
Heath DA: Hypercalcemia and malignancy. Ann Clin Biochem 13:555, 1976.
Rao DS, Frame B, Block MA, Parfitt AM: Primary hyperparathyroidism. A cause of hypercalciuria and renal stones in patients with medullary sponge kidney. JAMA 237:1353, 1977.
Gremillion DH, Kee JW, Mcintosh DA: Hyperparathyroidism and medullary sponge kidney. JAMA 237:436, 1977.
Vaishnava H, Rizvi SNA: Primary hyperparathyroidism associated with nutritional osteomalacia. Am J Med 45:640, 1976.
Keynes WM, Caird FI: Hypocalcemic primary hyperparathyroidism. Br Med J 1:208, 1970.
Dent CE, Jones PE, Mullan DP: Masked primary (or tertiary) hyperparathryroidism. Lancet 1:1161, 1975.
Woodhouse NJY, Doyle FH, Joplin GF: Vitamin D deficiency and primary hyperparathyroidism. Lancet 2:282, 1971.
Levi J, Massry SG, Coburn JW, Llach F, Kleeman CR: Hypocalcemia in magnesium depleted dogs: Evidence for reduced responsiveness to parathyroid hormone and relative failure of parathyroid gland function. Metabolism 23:323, 1974.
Cope D, Culver PJ, Mixter CG, Nardi GL: Pancreatitis — a diagnosis clue to hyperparathyroidism. Ann Surg 145:857, 1957.
Lever EG: Primary hyperparathyroidism masked by hypothyroidism. Am J Med 74:144, 1983.
Muldowney FP, Freaney R, McMullin JP, Towers RP, Spillane A, O’Connor P, O’Donohoe P, and Moloney M: Serum ionized calcium and parathyroid hormone in renal stone disease. Q J Med 45:75, 1976.
Pak CYC, Nicar MJ, Peterson R, Zerwekh JE, Snyder W: A lack of unique pathophysiologic background for nephrolithiasis of primary hyperparathyroidism. J Clin Endocrinol Metab 53:536, 1981.
Broadus AF, Horst RL, Lang R, Littledike ET, Rassmussen H: Circulating 1,25 dihydroxyvitamin D in primary hyperparathyroidism. N Engl J Med 302:421, 1980.
Edis AJ, Evans TC Jr: High-resolution, real-time ultrasonography in the preoperative location of parathyroid tumors. Pilot study. N Engl J Med 301:532, 1979.
Brewer WH, Walsh JW, Newsome HH Jr: Impact of sonography on surgery for primary hyperparathyroidism. Am J Surg 145:270, 1983.
Ferlin G, Borsato N, Camerani M, Conte N, Zotti D: New perspectives in localizing enlarged parathyroids by technetium-thallium subtraction scan. N Nucl Med 24:438, 1983.
Etiology and treatment of primary hyperparathyroidism (editorial). Lancet 1:367, 1983.
Brennan MF, Doppman JL, Marx SJ, Spiegel AM, Brown EM, Aurbach GD: Reoperative parathyroid surgery for persistent hyperparathyroidism. Surgery 83:669, 1983.
Doppman JL, Lawrence E, Mallette MD, Marx SJ, Monchik JM, Broadus A, Spiegel AM, Beazley R, Aurbach GD: The localization of abnormal mediastinal parathyroid glands. Radiology 115:31, 1975.
Wolverson MK, Sundaram M, Eddelston B, Prendergast J: Diagnosis of parathyroid adenoma by computed tomography for localization of parathyroid adenomas. J Comput Assist Tomogr 5:818, 1981.
Whitley NO, Bohlman M, Connor TB, McCrea ES, Mason GR, Whitley J E: Computed tomography for localization of parathyroid adenomas. J Comput Assist Tomogr 5:812, 1981.
Foley TP Jr, Harrison HC, Arnaud CD, Harrison HE: Familial benign hypercalcemia. J Pediatrics 81:1060, 1972.
Marx SJ, Spiegel AM, Brown EM, Koehler JO, Gardner DG, Brennan MF, Aurbach GD: Divalent cation metabolism. Familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism. Am J Med 65:235, 1978.
Marx SJ, Spiegel AM, Brown EM, Windeck R, Gardner DG, Downs RW Jr, Attie M, Aurbach GD: Circulating parathyroid hormone activity: Familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism. J Clin Endo Metab 47:1190, 1978.
Davies M, Klimiuk PS, Adams PH, Lumb GA, Large DM, Anderson DC: Familial hypocalciuric hypercalcemia and acute pancreatitis. Br Med J 282:1023, 1981.
Stote RM, Smith LH, Wilson DM, Dube WJ, Goldsmith RS, Arnaud CD: Hydrochlorothiazide effects on serum calcium and immunoreactive parathyroid hormone concentrations. Studies in normal subjects. Ann Intern Med 77:587, 1972.
Hossain M: Vitamin D intoxication during treatment for hypoparathyroidism. Lancet 1:1149, 1970.
Hughes MR, Baylink D, Jones PG, Haussler MR: Radioligand receptor assay for 25-hydroxyvitamin D2/D3, and 1-alpha 25-dihydroxyvitamin D2/D3. Application to hyper-vitaminosis D. J Clin Invest 58:61, 1976.
Counts SJ, Baylink DJ, Shen FH, Sherrard DJ, Hickman RO: Vitamin D intoxication in an anephric child. Ann Int Med 82:196, 1975.
Papapoulos SE, Clemens TL, Fraher LJ, Lewin IG, Sandler LM, O’Riordan JLH: 1,25 dihydroxycholecalciferol in the pathogenesis of the hypercalcemia of sarcoidosis. Lancet 1:627, 1979.
Bell NH, Stern PH, Pantzer E, Sinha TK, DeLuca HF: Evidence that increased circulating 1-alpha 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. J Clin Invest 64:L218, 1979.
Barbour GL, Coburn JW, Slatopolsky E, Norman AW, Horst RL: Hypercalcemia in an anephric patient with sarcoidosis: Evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N Engl J Med 305:440, 1981.
Adams JS, Sharma OP, Singer FR: Metabolism of 25-hydroxyvitamin D3 by alveolar macrophages in sarcoidosis. Clin Res 31:499A, 1983.
Baxter JD, Bondy PK: Hypercalcemia of thyrotoxicosis. Ann Intern Med 65:429, 1966.
Burman KD, Monchik JM, Earll JM, Wartofsky L: Ionized and total serum calcium and parathyroid hormone in hyperthyroidism. Ann Intern Med 84:668, 1976.
Mosekilde J, Christensen MS: Decreased parathyroid function in hyperthyroidism: Interrelationships between serum parathyroid hormone, calcium-phosphorus metabolism and thyroid function. Acta Endocrinology 84:566, 1977.
Fritzel D, Malleson A, Marks V: Plasma levels of ionized calcium and magnesium in thyroid disease. Lancet 1:1360, 1977.
Krane SM, Brownell GL, Stanbury JB, Corrigon H: The effect of thyroid disease on calcium metabolism in man. J Clin Invest 35:874, 1956.
Adams PH, Jowsey J, Kelly PJ, Riggs BL, Kinney VR, Jones JD: The effects of hyperthyroidism on bone and mineral metabolism in man. Q J Med 36:1, 1967.
Mundy GR, Shapiro JL, Bandelin JC, Canalis EM, Raisz IG: Direct stimulation of bone resorption by thyroid hormones. J Clin Invst 58:529, 1975.
Rude RK, Oldham SB, Singer FR, Nicoloff JT: Treatment of thyrotoxic hypercalcemia with propranolol. N Engl J Med 294:431, 1976.
Finlayson JF, Casey JH: Hypercalcemia and multiple pheochromocytomas. Ann Intern Med 82:810, 1975.
Heath H, Edis AJ: Pheochromocytoma associated with hypercalcemia and ectopic secretion of calcitonin. Ann Intern Med 91;208, 1979.
Jorgensen H: Hypercalcemia in adrenocortical insufficiency. Acta Med Scand 193:175, 1973.
Tuttle SG, Figueroa WG: Hypercalciuria associated with reduction in corticoid therapy after prolonged administration of prednisone and after bilateral adrenalectomy for Cushing’s syndrome. J Clin Invest 37:937, 1958.
Nadarajah A, Hartog M, Redfern B, Thalassinos N, Wright AD, Joplin GE, Fraser TR: Calcium metabolism in acromegaly. Br Med J 4:797, 1968.
Sjoberg HE: Retention of oral 45calcium in acromegaly. Horm Metab Res 1:136, 1969.
Riggs BL, Randall RV, Wahner HW, Jowsey J, Kelly PM, Singh M: The nature of the metabolic bone disorder in acromegaly. J Clin Endocrinol Metab 34:911, 1972.
Eskildsen PC, Lund B, Sorensen OH, Lund BI, Bishop JE, Norman AW: Acromegaly and vitamin D metabolism: Effect of bromocriptine treatment. J Clin Endocrinol metab 41:484, 1979.
Hirose S, Kobayashi K, Kajikawa K, Sawabu N, Takeuchi J: A case of watery diarrhea, hypokalemia and hypercalcemia associated with nonulcerogenic islet cell tumor of the pancreas. Am J Gastroenterology 64:382, 1975.
Frame B, Jackson CE, Reynolds WA, Umphrey JE: Hypercalcemia an skeletal effects in chronic hypervitaminosis A. Ann Int Med 80:44, 1974.
Chertow BS, Williams GA, Norris RM, Baker GR, Hargis GK: Vitamin A stimulation of parathyroid hormone: Interactions with calcium, hydrocortisone, and vitamin E in bovine parathyroid tissues and effects of vitamin A in man. Eur J Invest 7:307, 1977.
Broadus AE, Mahaffey JE, Bartter FC, Neer RM: Nephrogenous cyclic adenosine monophosphate as a parathyroid function test. J Clin Invest 60:771, 1977.
Broadus AE, Horst RL, Lang R, Travis, Littledike ET, Rasmussen H: The importance of circulating 1,25 dihydroxy vitamin D, and renal stone formation in primary hyperparathyroidism. N Eng J Med 302:421, 1980.
Adami S, Milroy EJG, O’Riordan JLH: Primary hyperparathyroidism. In: BEC Nordin, ed, Metabolic Bone and Stone disease. Churchill Livingstone, New York, p 112, 1984.
Broadus AE, Deftos LJ, Bartter FC: Effects of the intravenous administration of calcium on nephrogenous cyclic AMP. Use a parathyroid suppression test. J Clin Endocrinol Metab 46:477, 1978.
Broadus AF, Horst RL, Littledike ET, Mahaffey JE, Rasmussen H: Primary hyperparathyroidism with intermittent hypercalcemia: Serial observations and simple diagnosis by means of an oral calcium tolerance test. Clin Endocrinol 12:225, 1980.
Watson L, Moxham J, Fraser P: Hydrocortisone suppression test and discriminant analysis in different diagnosis of hypercalcemia. Lancet 1:1320, 1980.
Suki WN, Yium JJ, Von Minden M, Saller-Hebert C, Ecknoyan G, Martinez-Maldonado M: Acute treatment of hypercalcemia with furosemide. N Engl J Med 283:836, 1970.
Elliott TG, McKenzie WH: Treatment of hypercalcemia. Drug Intell Clin Pharm 17:12, 1983.
Brickman AS, Massry SG: Changes in serum and urinary calcium during treatment with hydrochlorothiazide. J Clin Invest 51:945, 1972.
Parfitt AM: The interaction of thiazide diuretics with parathyroid hormone and vitamin D — studies in patients with hypoparathyroidism. J Clin Invest 51:1879, 1972.
Goldsmith RS, Ingbar SH: Inorganic phosphate treatment of hypercalcemia of diverse etiologies. N Engl J Med 274:1, 1966.
Herbert LA, Lemann J Jr, Petersen JR, Lennon EJ: Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest 45:1886, 1966.
Massry SG, Mueller E, Silverman AG, Kleeman CR: Inorganic phosphate treatment with hypercalcemia. Arch Intern Med 121:307, 1968.
Carrol E, Pechet M: Stimulation of bone formation by inorganic phosphate and inhibition of bone resorption by thyrocalcitonin. J Clin Invest 46:1043, 1967.
Breuer RI, Le Bauer J: Caution in the use of phosphates in the treatment of severe hypercalcemia. J Clin Endocrinol 27:695, 1967.
Alijouni K, Rosenfeld PS: Treatment of hypercalcemia. Drug Ther 4:103, 1974.
Lee DBN, Zawada ET, Kleeman CR: The pathophysiology and clinical aspects of hypercalcemic disorders. Western J Med 129:278, 1978.
Yendt ER: Disorders of calcium, phosphorus, and magnesium metabolism. In: Maxwell MH, Kleeman CR, eds, Clinical Disorders of Fluid and Electrolyte Metabolism. McGraw-Hill, New York p 416, 1972.
Massry SG, Mueller E, Silverman AG, Kleeman CR: Inorganic phosphate treatment for hypercalcemia. Arch Intern Med 121:307, 1968.
Coburn JW, Brickman AS, Massry SG: Medical treatment in primary and secondary hyperparathyroidism. Semin Drug Treatment 2:117, 1972.
Brautbar N, Luboshitzky R: Combined calcitonin and oral phosphate treatment for hypercalcemia in multiple myeloma. Arch Intern Med 137:914, 1977.
Fleisch H, Felix R: Diphosphonates. Calif Tissue Int 27:91, 1979.
Shane E, Baquiran DC, Bilezikian J P: Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Intern Med 95:23, 1981.
Breukelen FJM, Bijvoet OLM, Van Oosterom AT: Inhibition of osteolytic bone lesions by (3-amino-l-hydroxypro-pyliden)-1, l-biphosphonate (A.P.D) Lancet 1:803, 1979.
Siris ES, Sherman WH, Baquiran DC, Schlatter JP, Osserman EF, Canfield RE: Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Eng J Med 302:310, 1980.
Jacobs TP, Siris ES, Bilezikian JP, Baquiran DC, Shane E, Canfield RE: Hypercalcemia of malignancy: Treatment with intravenous dichloromethylene diphosphonate. Ann Intern Med 94:312, 1981.
Chapuy MC, Meunier PJ, Alexandre CM, Vignon EP: Effects of disodium dichlormethylene diphosphonate on hypercalcemia produced by bone metatases. J Clin Invest 65:1243, 1980.
Canfield R, Rosner W, Shinner J, et al.: Diphosphonate therapy of Paget’s disease of bone. J Clin Endocrinol Metab 44:96, 1977.
Frijlink WB, TeVelde J, Bijvoet OLM, Heynen G: Treatment of Paget’s disease with (3-amino-l-hyroxypropylidene)-1, l-biphosphonate (A.P.D.) Lancet 1:799, 1979.
Jaeger P, Williams J, Clemens LT, Hayslett PJ: Evidence that calcitonin stimulates 1,25-dihydroxy production and intestinal absorption of calcium in vivo. J Clin Invest 78:456, 1986.
Silva OL, Becker KL: Salmon calcitonin in the treatment of hypercalcemia. Arch Intern Med 132:337, 1973.
Habener JF, Singer FR, Deftos LJ, Potts JT: Immunological stability of calcitonin in plasma. Endocrinology 90:952, 1972.
Singer FR, Aldred JP, Neer RM, Krane SM, Potts JT: An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 51:2331, 1972.
Neer RM, Habener JF, Peacock N, Murray T: Escape from calcitonin (CT) during therapy of hypercalcemia. Clin Res 18:676, 1970.
Dube WJ, Goldsmith RS, Arnaud SB: Hyperparathyroidism secondary to long term therapy of Paget’s disease in bone with calcitonin. In: RV Talmag, PL Munson, eds, Calcium, Parathyroid Hormone and the Calcitonins. Excerptal Medical, Amsterdam, p 113, 1972.
Au WYW: Calcitonin treatment of hypercalcemia due to parathyroid carcinoma — synergistic effect of prednisone on long-term treatment of hypercalcemia. Arch Int Med 135: 1594, 1975.
Caro JF, Besarab A, Glennon JA: Symptomatic hypocalcemia following combined calcitonin and mithramycin therapy for hypercalcemia due to malignancy. Cancer Treat Rep 62:1561, 1978.
Deftos LJ, Potts JT: Parathyroid hormone, thyrocalcitonin, vitamin D, bone and mineral metabolism. In: PL Bondy, ed, Duncan’s Disease of Metabolism. WB Saunders, Philadelphia, p 1225, 1974.
Reilly MJ, Kepler JA, Poor DM, Lande NI, Rolf BI, Douglas PM (eds): Am Hosp Form Serv 2:68, 1980.
Jee WSS, Roberts WE, Park HZ: Interrelated effects of glucocorticoid and parathyroid hormone upon bone remodelling. In: RV Talmage, PL Munson, eds, Calcium Parathryoid Hormone and the Calcitonins. Excerpta Medica, Amsterdam, p 430, 1972.
Collins EJ, Garett E, Johnston RL: Effect of adrenal steroids on radiocalcium metabolism in dogs. Metabolism 11:716, 1962.
Loak H: The action of corticosteroid on the renal reabsorption of calcium. Acta Endocrinol 34:60, 1960.
Tashian AH, Voelkel EF, McDonough J: Hydrocortisone inhibits prostaglandin production by mouse fibrosarcoma cells. Nature 258:739, 1975.
Mundy GR, Rick ME, Turcotte R, Kowalski MA: Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia: Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapy. Am I Med 5:600, 1978.
Potts JT: Disorders of the parathyroid gland. In: KJ Isselbacher, RD Adams, E Braunwald, RG Petersdorf, JD Wilson, eds, Harrison’s Principles of Internal Medicine. McGraw-Hill, p 1838, 1980.
Kennedy BJ: New York, Metabolic and toxic effects of mithramycin during tumor therapy. Am I Med 49:494, 1970.
Singer FR, Neer RM, Murray JM, Keutmann HT, Deftos LJ, Potts JT: Mithramycin treatment of intractable hypercalcemia due to parathryoid carcinoma. N Engl I Med 283:634, 1970.
Elias EG, Reyn G, Mittelman A: Control of hypercalcemia with mithramycin. Ann Surg 175:431, 1972.
Smith IE, Powles TJ: Mithramycin for hypercalcemia associated with myeloma and other malignancies. Br Med I 1:268, 1975.
Parsons V, Baum M: Effect of mithramycin on calcium and hydroxyproline metabolism in patients with malignant disease. Br Med J 1:474, 1967.
Brereton HD, Halushk PV, Alexander RW, Mason DM, Keiwer HE, DeVita VT Jr: Indomethacin-responsive hypercalceia in a patient with renal-cell adenocarcinoma. NEngJ Med 291:83, 1974.
Robertson RP, Baylink DJ, Marini JJ, Adkison W: Elevated prostaglandins and suppressed parathyroid hormone assodated with hypercalcemia and renal cell carcinoma. J Clin Endocrinol Metab 41:164, 1975.
Brenner DE, Harvey HA, Lipton A, Demers L: A study of prostaglandin E2, parathormone and response to indomethacin in patients with hypercalcemia of malignancy. Cancer 44:556, 1982.
Atkins D, Ibbotson KJ, Hillier K, Hunt NH, Hammonds JC, Martin TJ: Secretion of prostaglandins as bone resorbing agents by renal cortical carcinoma in culture. Br J Cancer 36:601, 1971.
Prescott LF: Anti-inflammatory analgesics and drugs used in rheumatoid arthritis and gout. In: MNG Dukes, ed, Meyler’s Side Effects of Drugs. American Elsevier, New York, pp 217, 1975.
Nolph KD, Stolt M, Maher JF: Calcium free peritoneal dialysis treatment of vitamin D intoxication. Arch Int Med 128:809, 1971.
Stolz ML, Nolph KD, Maher JF: Factors affecting calcium removal with calcium-free peritoneal dialysis. J Lab Clin Med 78:389, 1971.
Scholz D, Purnell D: Asymptomatic primary hyperparathyroidism: A 10-year prospective study. Mayo Clin Proc 56:473, 1981.
Posen S, Clifton-Bligh P, Reeve TS, Wagstaffe C, Wilkinson M: Is parathyroidectomy of benefit in primary hyperparathyroidism? In: B Frame, JT Potts, eds, Clinical Disorders of Bone and Mineral Metabolism. Excerpta Medica, Amsterdam, p 154, 1983.
Neer R: Natural history of untreated hyperparathyroidism. Presented at Symposium on Clinical Disorders of Bone and Mineral Metabolism. May 1983.
Sherwood JK, Ackroyd FW, Garcia M: Effect of Cimetidine on circulating parathyroid hormone in primary hyperparathyroidism. Lancet 1:616, 1980.
Caro JF, Castro JH, Glennon JA: Effect of long-term propranolol administration on parathyroid hormone and calcium concentration in primary hyperparathyroidism. Ann Int Med 91:740, 1979.
Rude RK, Oldham SB, Singer FR, Nicoloff JT: Treatment of thyrotoxic hypercalcemia with propranolol. N Eng J Med 294:431, 1976.
Sigurdsson G, Woodhouse NJY, Taylor S, Joplin GF: Stilboestrol diphosphonate in hypercalcemia due to parathryoid carcinoma. Br Med J 1:27, 1973.
Mundy GR, Wilkinson R, Heath DA: A comparative study of available medical therapy for hypercalcemia malignancy. Am J Med 74:421, 1983.
Van Holten-Verzamdvoort A, Harinck HIJ, Hermans J, Cleton RJ, Bijvoet OLM: Supportive bisphosphonate treatment reduces morbidity from bone lesions in breast cancer (abstract). ASBMR, Bone Mineral Research Congress, Abs No. 390, Indianapolis, 1987.
Glover D, Riley L, Carmichael K, et al.: Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). N Engl J Med 309:1137, 1983.
Wolf J, Attie M, Fallar M, Goldfarb S: Studies of the hypocalcemic action of WR-2721. Clin Res 32:412, 1984.
Glover JD, Shaw L, Glick J, Slatopolsky E, Weiler C, Attie M, Goldfarb S: Treatment of hypercalcemia in parathyroid cancer with WR2721, S-2-(3-aminopropylamine) ethyl-phosphorothoric acid. Ann Int Med 103:55, 1985.
Weiss J, Wolf J, Slatopolsky E, Fallar M, Attie M, Goldfarb S: Sustained hypocalcemia, inhibition of PTH secretion and correction of Vitamin D induced hypercalcemia with chronic administration of WR-2721 (abstract). Kidney Int 27:129(S), 1985.
Hunt BJ, Yendt ER: The response of hypercalcemia in sarcoidosis to chloroquine. Ann Int Med 59:554, 1963.
O’Leary JT, Jones G, Yip A, Lohnes D, Cohanim M, Yendt E: The effects of chloroquine on serum 1,25-dihydroxy vitamin D and calcium metabolism in sarcoidosis. N Engl J Med 315:12, 1986.
Glass RA, Eil CH: Ketoconazole-induced reduction in serum 1,25-dihydroxy vitamin D. J Clin Endocrinol Metabolism 63:766, 1986.
Henry HL: Effect of ketoconazole and myconazole on 25-hydroxy D3 metabolism by cultured chick kidney cells. J Steroid Biochem 23:91, 1985.
Mishoulam HJ, Lad TE, Khan A, Kukla LJ, Abrahamson EC, McGuire WP, Kukreja SC: Effect of cisplatinum on hypercalcemia of malignancy. Clin Res 31:778a, 1983.
Kukla LJ, Abrahamson EC, Shevrin DH, Lad TE, Mcguire WP, Kukreja SC: Cisplatinum as treatment for humoral hypercalcemia of malignancy in an athymic mouse model. Clin Res 31:739A, 1983.
Walsh FB, Murray RG: Ocular manifestations of disturbances in calcium metabolism. Am J Ophth 36:1657, 1953.
Barr DP, MacBride CM, Sanders TE: Tetany with increased intracranial pressure and papilledema. Results from treatment with hydrotachysterol. Trans Assoc Am Phys 53:227, 1938.
Ireland AW, Hornbrook JW, Neale FC, Posen S: The crystalline lens in chronic surgical hypoparathyroidism. Arch Int Med 122:408, 1969.
Camp JD: Symmetrical calcification of the cerebral basal ganglia, its roentgeneologic significance in the diagnosis of parathyroid insufficiency. Radiology 49:568, 1947.
Levine P: Intracranial calcification associated with hypoparathyroidism. Bull NY Acad Med 38:632, 1962.
Chopra D, Janson P, Sawin CT: Insensitivity to digoxin associated with hypocalcemia. N Eng J Med 296:917, 1977.
Eipe J, Johnson SA, Kiamko RT, Bronksy D: Hypoparathyroidism following 131I therapy for hyperthyroidism. Arch Intern Med 121:270, 1968.
Sagel J, Epstein S, Kalk J, Von Mieghen W: Radioactive iodine therapy for thyrotoxicosis at Groote Schuur Hospital over a 6 year period. Postgrad Med J 48:308, 1972.
Robertson GM, Moore EW, Switz DM, Sizemore GW, Estep HL: Inadequate parathyroid response in acute pancreatitis. N Engl J Med 194:512, 1976.
Haldiman B, Goldstein DA, Akam M, Massry SG: Renal function and blood levels of divalent ions in acute pancreatitis. A prospective study in 99 patients. Miner Electolyte Metab 3:190, 1980.
Horwitz CA, Myers LWP, Foote FW: Secondary malignant tumors of the parathyroid glands. Report of 2 cases with associated hypoparathyroidism. Am J Med 52:797, 1972.
Brezis M, Shalev O, Leibel B, Berenheim J, Ben Ishay D: Phosphorus retention and hypoparathyroidism associated with transfusion and iron overload in thalassemia. Miner Electrolyte Metab 4:57, 1980.
Drake TG, Albright F, Bauer W, Castleman B: Chronic idiopathic hypoparathyroidism. Report of 6 cases with autopsy findings. Ann Intern Med 12:1751, 1939.
Spinner MW, Blizzard RM, Childs B: Clinical and genetic heterogeneity in idiopathic Addison’s disease and hypoparathyroidism. J Clin Endocrinol Metab 28:795, 1968.
Wilson PW, Buckley CE, Eisenbarth GS: Disordered immune function in patients with polyglandular failure. J Clin Endocrinol Metab 52:284, 1981.
Nusynowitz ML, Frame B, Kolb FO: The spectrum of the hypoparathyroid states. A classification based on physiologic principles. Medicine (Baltimore) 55:105, 1976.
Klahr S, Slatopolsky E: Urinary phosphate and cyclic AMP in pseudohypoparathyroidism. In: SG Massry, E Ritz, A Rapado, eds, Homeostasis of Phosphate and Other Minerals. Plenum, New York, p 173, 1977.
Chase LR, Melson GL, Aurbach GD: Pseudohypoparathyroidism: Defective excretion of 3′5′-AMP in response to parathyroid hormone. J Clin Invest 48:1832, 1969.
Farfel Z, Brickman AS, Kaslow HR, Brothers V, Bourne H: Defect of receptor cyclase coupling protein in pseudo-hypoparathryoidism. N Eng J Med 303:237, 1980.
Bourne HR, Kaslow HR, Brickman AS, Farfel Z: Fibroblast defect in pseudohypoparathyroidism Type I. Reduced activity of receptor cyclase coupling protein. J Clin Endocrinol Metab 53:636, 1981.
Drezner M, Neelon FA, Lebovitz HE: Pseudohypoparathyroidism Type II. A possible defect in the reception of cyclic AMP signal. N Eng J Med 289:1056, 1973.
Rodriguez HJ, Villareal H, Klahr S, Slatopolsky E: Pseudohypoparathyroidism Type II. Restoration of normal renal responsiveness to parathyroid hormone by calcium administration. J Clin Endocrinol Metab 39:693, 1974.
Daneman D, Kooh SW, Fraser D: Hypoparathyroidism in childhood. Clin Endocrinol Metab 11:211, 1982.
Kolb FO, Steinbach HL: Pseudohypoparathyroidism with secondary hyperparathyroidism and osteitis fibrosa. J Clin Endocrinol 22:59, 1962.
Drezner MK, Neelon FA, Haussier M, McPherson HT, Lebovitz HE: 1,25-dihydroxycholecalciferol deficiency: The probable cause of hypocalcemia and metabolic bone disease in pseudo hypoparathyroidism. J Clin Endocrinol Metab 42:621, 1976.
Pitkin RM: Calcium metabolism in pregnancy. A review. Am J Obstet Gynecol 121:724, 1975.
Tsang RC, Light IJ, Sutherland JM, Kleinman LI: Possible pathogenetic factors in neonatal hypocalcemia of prematurity. J Pediatr 82:423, 1973.
Tsang RC, Chen I-W, Friedman MA, Chen I: Neonatal parathyroid function: Role of gestational age and postnatal age. J Pediatr 83:728, 1973.
Barltrop D: Neonatal hypocalcemia. Postgrad J 51 (Suppl 3): 7, 1975.
Rao DS, Parfitt AM, Kleerekoper M, Pumo BS, Mathews M, Frame B: Dissociation of cAMP and Phosphaturic response to PTH in human vitamin D deficiency. An acquired disorder simulating pseudohypoparathyroidism. Presented at VII Int. Conference on Calcium Regulating Hormones, Kobe, Japan, 1983.
Medalle K, Waterhouse C: A magnesium deficient patient presenting with hypocalcemia and hypophosphatemia. Ann Intern Med 79:76, 1973.
Porter RH, Cox BA, Heaney D, Hostetter TH, Stinebaugh BJ, Suki W: Treatment of hypoparathyroid patients with chlorthalidone. N Eng J Med 298:578, 1978.
Peterson P, Gray P, Tolmn KG: Calcium balance in drug-induced osteomalacia: Response to vitamin D. Clin Pharm Ther 19:63, 1976.
Purnell DC, Scholtz DA, Smith LH, Sizemore GW, Black BM, Goldsmith RS, Arnaud CDP: Treatment of primary hyperparathyroidism. Am J Med 56:800, 1974.
Parfitt AM: Adult hypoparathyroidism. Treatment with calcifediol. Arch Int Med 138:874, 1978.
Nagant De Deuxchaisnes C: Hyperparathyroidism. In: LV Avioli, SM Krane, eds, Metabolic Bone Disease, Vol 2. Academic Press, New York, 1978.
Bilezikian JP: Parathyroid hormone related peptide in sickness and in health. N Engl J Med 322:1151–1153, 1990.
Budayr AA, Nissenson RA, Kline RF, et al.: Increased serum levels of a parathyroid hormone-like peptide in malignancy associated with hypercalcemia. Ann Intern Med 111:807–812, 1989.
Henderson JE, Shustic C, Kramer R, et al.: Circulating concentrations of parathyroid hormone-like peptide in malignancy and hyperparathyroidism. J Bone Min Res 5:105–113, 1990.
Burtis WJ, Brady BS, Orloff JJ, et al.: Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 322:1106–1112, 1990.
Lindall AW, Elting J, Ells J, Rouse BA: Estimation of biologically activate intact parathyroid hormone in normal and hyperparathryoid sera by sequential N-terminal immunoextraction and mid region radioimmunoassay. J Clin Endocrinol Metab 57:1007, 1983.
Nussbaum SR, Zahradink RJ, Lavinge JR, et al.: Highly sensitive two site immunoradiometric assay of parathyrin and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 8:1364–1367, 1987.
Blind, E, Schmidt-Gayk H, Scharia S, et al.: Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a midregion assay. J Clin Endocrinol Metab 67:353–360, 1988.
Patron P, Gardin J-P, Paillard M: Renal mass and reserve of vitamin D: determinants in primary hyperparathyroidism. Kidney Int 31:1174–1180, 1987.
Potts JT Jr: Management of asymptomatic hyperparathyroidism. J Clin Endocrinol Metab 70:1489–1493, 1980.
Ralston SH, Gallacher SJ, Patel U, et al.: Cancer associated hypercalcemia, morbidity and mortality. Clinical experience in 126 patients. Ann Intern Med 112:499–504, 1990.
Harinck HIJ, Bijvoet OLM, Plantingh AST, et al.: Role of bone and kidney in tumour induce hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am J Med 82:1133–1142, 1987.
Ralston SH, Dryburgh FJ, Cowan RA, et al.: Comparision of aminohydroxypropylidene diphosphonate, mithramycin and corticosteroids/calcitonin in treatment of cancer associated hypercalcemia. Lancet 2:907–910, 1985.
Etridronate disodium: A new therapy for hypercalcemia of malignancy. Am J Med 82 (2A):1–78, 1987.
Warrell RP Jr, Israel R, Frisone M, et al.: Gallium nitrate for acute treatment of cancer related hypercalcemia: a randomized double blind comparison with calcitonin. Ann Intern Med 108:669–674, 1988.
Warrell RP Jr, Murphy WK, Schulman P, O’Dwyer PJ: Gallium nitrate vs. etridronate for acute treatment of cancer related hypercalcemia randomized double blind study. J Bone Min Res 5:S271, 1990.
Yamamoto M, Takuwa Y, Masuko S, Ogata E: Effects of endogenous and exogenous parathyroid hormone on tubular reabsorption of calcium in pseudohypoparathyroidism. J Clin Endocrinol Metab 66:618–625, 1988.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Kluwer Academic Publishers
About this chapter
Cite this chapter
Halabe, A., Sutton, R.A.L. (1991). Disorders of Calcium Metabolism. In: Suki, W.N., Massry, S.G. (eds) Therapy of Renal Diseases and Related Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0689-4_5
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0689-4_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8027-9
Online ISBN: 978-1-4613-0689-4
eBook Packages: Springer Book Archive